在建设产业高地方面，22个南药品种获得全国名特优新农产品称号，创建4个国家级和18个省级南药产 业园。2024年规模以上中药工业实现营收655.59亿元。 在建设对外交流合作高地方面，组织召开粤港澳大湾区中医药传承创新发展大会，搭建高质量交流合作 平台，9个品种超5万瓶院内制剂跨境调剂至澳门使用，粤澳合作中医药科技产业园累计完成24款中成药 产品的国际注册和备案。 通过管理体制机制改革，广东夯实中医药发展基础。所有地市和95%的县（市、区）均设立中医药管理 机构，云浮、茂名两市市县两级设置"中医药事业发展中心"全覆盖。共有5家二级以上公立综合医院转 型为中医类别医院，中医医疗机构布局进一步优化。 （来源：中国中医药网） 转自：中国中医药网 本报讯（记者 秦宇龙）自全面启动国家中医药综合改革示范区建设以来，广东省政府印发示范区建设 实施方案，成立由省长任组长的示范区建设工作领导小组。通过建设"五大高地"，构建起中医药高质量 发展格局。2024年中医类门诊服务总量占全省门诊量的26.2%，规模以上中药工业实现营收655.59亿 元。 在建设医疗高地方面，14家医院进入全国三级公立中医医院绩效考核百强榜，80个专科 ...

转自：新华财经 在呼吸产品线，津药达仁堂共有102个品种。本次盛会上，津药达仁堂以呼吸领域核心产品清咽滴丸、清肺消炎丸为重点，携特装展位亮相。大会主席钟 南山院士、张伯礼院士亲临展位参观交流，对公司深厚的品牌底蕴与卓越的产品品质给予高度评价。展位现场人气汇聚，中医药的深厚底蕴与老字号的新 活力共绽光彩。 津药达仁堂表示，未来将以守护全民呼吸健康为使命，围绕清咽滴丸与清肺消炎丸两大呼吸品种，紧密协同共同体各方力量，持续发挥中药创新优势，切 实将中医药这一民族瑰宝保护好、发掘好、发展好、传承好，全力助推呼吸健康事业蓬勃发展，携手共创健康新未来。（李禹霏） 津药达仁堂集团总经理助理、营销负责人林跃群登台，钟南山院士、张伯礼院士为企业代表授牌。呼吸健康共同体的成立，旨在推动中医药高质量发展， 更好满足临床对优质呼吸类药物的需求。 津药达仁堂作为拥有500年历史积淀的中医药企业，拥有丰富的产品资源——599个药品批文，其中122个为独家品种，覆盖心脑健康、呼吸健康、消化健 康等领域，扎实的产品矩阵和确切的疗效，持续为全民健康事业注入动力。 编辑：王姝睿 12月6日，以"中西医协同·产学研创新：共筑呼吸健康新格局"为主题 ...

Core Insights - The article highlights the progress and achievements of Dongying City in the development of traditional Chinese medicine (TCM) in alignment with national and provincial policies [1][5]. Group 1: Reform and Development - Dongying has established a monthly monitoring mechanism for high-quality TCM development indicators, enhancing the management and performance of public TCM hospitals [3]. - Several projects from Dongying have been selected as provincial and national pilot projects, including the "Information Technology Leading and Supporting High-Quality Development of TCM" project, which has been recognized by the National Administration of Traditional Chinese Medicine [1][3]. Group 2: Service Capacity and Accessibility - A total of 117 visits by expert TCM practitioners have been conducted since April, resulting in 1,348 prescriptions for traditional Chinese medicine pieces and 643 prescriptions for granules, significantly improving service capacity [3]. - All village clinics and community health service stations in Dongying now provide TCM services, expanding accessibility through the promotion of specialized therapies and suitable techniques [3]. Group 3: Cultural Promotion and Community Engagement - Dongying has established a provincial-level TCM cultural promotion and education base and has conducted various community health initiatives, serving over 26,000 people throughout the year [4]. - The city has implemented an integrated TCM diagnosis and treatment regulatory system, allowing real-time data collection and analysis across four levels of medical institutions [4]. Group 4: Future Directions - Dongying plans to continue deepening TCM reform and innovation, accelerating digital transformation, and promoting high-quality TCM services to contribute to the health development of the city [5].

Group 1: Overview of Traditional Chinese Medicine (TCM) Development in Zhejiang - Zhejiang is a major province for traditional Chinese medicine, with 4,599 TCM medical institutions, including 49 tertiary public TCM hospitals, ranking second in the country [1] - By 2024, total outpatient visits in public TCM hospitals are expected to reach 61.83 million, with inpatient discharges projected at 1.76 million [1] - Hangzhou has implemented a "smart TCM" initiative, enhancing healthcare services through technology, including a "smart tongue diagnosis" platform that has served over one million people [1] Group 2: Healthcare Policy and Insurance Support - Hangzhou's Medical Security Bureau has added 17 new TCM service projects and adjusted prices for 99 existing projects to optimize insurance payments for the public [2] - A dynamic pricing mechanism for TCM herbal pieces and formulations has been established to ensure reasonable pricing and quality assurance [2] - The city has initiated traceability management for TCM herbal pieces, with two batches of 15 medicinal materials undergoing traceability work, four of which are nearing clinical application [2] Group 3: Integration of TCM with Lifestyle and Tourism - TCM tea drinks and markets are gaining popularity, with Hangzhou focusing on creating engaging cultural and tourism experiences around TCM [2] - Notable initiatives include the introduction of "Chinese medicine coffee" and seasonal health activities that attract significant tourist engagement [2] - The city has hosted over 300 TCM-themed cultural markets, integrating health services, heritage experiences, and creative product sales, with events attracting up to 30,000 visitors in a single night [3]

Group 1 - The sixth China (Gansu) Traditional Chinese Medicine Industry Expo will be held from August 23 to 25 in Longxi County, Dingxi City, Gansu Province [1] - The theme of the expo is "Inheritance, Innovation, Open Sharing, Promoting High-Quality Development of Traditional Chinese Medicine," focusing on marketization, specialization, and internationalization [2] - The expo will feature 10 activities, including an opening ceremony, policy interpretation, and forums on various topics related to the development of traditional Chinese medicine [2] Group 2 - Gansu Province is a significant birthplace of traditional Chinese medicine and aims to build a trillion-yuan industry cluster, with the total scale of the traditional Chinese medicine industry chain expected to reach 97.2 billion yuan in 2024 [3] - The province's traditional Chinese medicine resources are characterized by high quality and rich variety, with a stable planting area of over 2 million acres and a total output of 500,000 tons, ranking first among prefecture-level cities in China [2] - Key traditional Chinese medicinal materials such as Angelica, Astragalus, and Codonopsis have significant planting areas, accounting for 60%, 40%, and 20% of the national total, respectively [2]

Core Viewpoint - The article highlights the resilience and growth of Yiling Pharmaceutical, a leading innovative traditional Chinese medicine company, following a challenging financial period, supported by favorable national policies and a strong focus on research and development. Financial Performance - In 2024, Yiling Pharmaceutical reported revenue of 6.513 billion yuan with a net loss of 0.725 billion yuan, but in Q1 2025, the company achieved revenue of 2.358 billion yuan and a non-net profit of 0.325 billion yuan, reflecting a year-on-year growth of 11.23% [2][3] - The company’s gross margin in Q1 2025 was 53.82%, an increase of 2.34 percentage points year-on-year, while the net margin was 13.82%, up by 1.85 percentage points [2][3] - Operating cash flow improved significantly, reaching 0.34 billion yuan in Q1 2025, nearly doubling the net profit for the same period [3] Debt and Receivables Management - By the end of 2024, accounts receivable stood at 1.225 billion yuan, down by 50% from the beginning of the year, while total liabilities decreased by 43.75% to 3.117 billion yuan [3] - The accounts receivable turnover days decreased to 55 days, down by 35 days year-on-year, indicating improved cash collection efficiency [3] Research and Development - Yiling Pharmaceutical's R&D investment exceeded 0.9 billion yuan in 2024, accounting for 13.9% of revenue, positioning the company as a leader in the industry [4][5] - Over the past six years, the cumulative R&D investment has approached 5 billion yuan, consistently exceeding industry averages [5] - As of the end of 2024, the company held 884 effective patents and had launched 17 patented traditional Chinese medicines covering eight major clinical disease systems [6][7] Product Development and Market Position - The company has received approval for new drugs targeting cardiovascular and respiratory diseases, with several products included in the national medical insurance directory [7][10] - Yiling Pharmaceutical is actively expanding its product portfolio, with ongoing clinical trials for six traditional Chinese medicines and over a hundred formulations in development [7][8] Policy Support and Industry Trends - The company benefits from supportive national policies aimed at revitalizing traditional Chinese medicine, including the inclusion of its products in the national medical insurance directory [10][11] - Yiling Pharmaceutical is also embracing digital transformation to enhance operational efficiency, completing significant research projects published in top medical journals [11] Strategic Vision - The company is evolving from a traditional medicine manufacturer to a health solution provider, aligning with national goals for high-quality development in the pharmaceutical industry [13]

Group 1 - Yiling Pharmaceutical actively responds to national policies and drives the upgrade of the traditional Chinese medicine industry through full industry chain innovation practices, achieving significant results in quality control, technological innovation, and international layout [1][3] - The company adopts a "company + base + farmer" model for the cultivation of medicinal materials, establishing over 60 standardized bases across seven major medicinal material production areas in China, covering more than 700,000 acres and over 40 varieties [1] - Yiling Pharmaceutical's quality control laboratory is equipped with advanced instruments, and has maintained a 100% annual inspection pass rate for its products, demonstrating its commitment to stringent quality standards [1][2] Group 2 - Research and innovation are core driving forces for the company's development, with R&D investment reaching 13.94% in 2024, significantly higher than the industry average [2] - The company has launched 17 patented traditional Chinese medicines, with 11 included in the national medical insurance directory and 5 in the national essential drug list, addressing major diseases such as cardiovascular and respiratory conditions [2] - Yiling Pharmaceutical has established international collaborations with institutions like Leiden University and Cardiff University, publishing over 300 SCI papers and promoting the global dissemination of traditional Chinese medicine culture [2][3] Group 3 - The company's practices span the entire industry chain of traditional Chinese medicine, showcasing a development philosophy of "inheriting the essence and maintaining innovation" [3] - The implementation of national policies is expected to usher in a golden period of high-quality development for the traditional Chinese medicine industry, with Yiling Pharmaceutical's efforts enhancing its competitiveness and driving industry improvement [3][5]

Core Insights - The new traditional Chinese medicine hospital in Linyi, Shandong, with a total investment of 260 million yuan, aims to set a new standard for TCM services in the Yimeng area [1] - The hospital is part of Linyi's "Five Comprehensive" project, focusing on specialized TCM development and the promotion of suitable TCM technologies [1] Group 1 - The new outpatient comprehensive building will serve as a model for high-quality TCM development in the region [1] - The hospital has established 12 National Medicine Halls in collaboration with 12 township health centers, enhancing TCM service accessibility [1] - The hospital has trained 74 individuals and cultivated 4 outstanding TCM talents in the Yimeng area [1] Group 2 - The hospital has conducted four phases of intensive training for over 500 individuals, covering 15 types of TCM techniques [2] - A collaborative medical system has been established, connecting the county hospital with township hospitals and village clinics [2] - Since its operation in July 2020, the hospital has distributed 2.6201 million doses of Chinese medicine and waived fees totaling 18.163 million yuan [2]